Immutep Ltd. IMMP 深 滬
已收盤 08-01 16:00:00 美东时间
1.72
-0.020
-1.15%
華盛通- 最 高1.73
- 今 開1.73
- 成交量 6.22万股
- 最 低 1.67
- 昨 收 1.74
- 總市值 2.51亿
- 52周最高 2.72
- 市盈率 靜 --
- 換手率 0.04%
- 52周最低 1.32
- 委 比 -84.08%
- 總股本 1.46亿
- 歷史最高 7.95
- 量 比 0.72
- 振 幅 3.45%
- 歷史最低 0.53
- 每 手 1
- 風險率 0.33%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Immutep Advances Oncology Trials with Promising Results
The latest update is out from Immutep Ltd ( ($AU:IMM) ). Immutep Limited has re...
07-30 07:18
Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer
Immutep Limited will present a poster on its pivotal TACTI-004 Phase III trial at the 2025 World Conference on Lung Cancer in Barcelona. The trial evaluates eftilagimod alfa (efti) combined with pembrolizumab and chemotherapy for first-line treatment of advanced or metastatic non-small cell lung cancer (NSCLC). The global trial will enroll approximately 750 patients across 150 sites in over 25 countries. The presentation will highlight the study ...
07-29 12:00
Immutep Announces Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025
Immutep Limited, a late-stage immunotherapy company, announces that three abstracts for clinical trials evaluating its MHC Class II agonist eftilagimod alfa (efti) have been accepted for presentation at the ESMO Congress 2025 in Berlin. The presentations include a Proffered Paper on the EFTISARC-NEO trial in soft tissue sarcoma, a poster on the INSIGHT-003 trial in non-small cell lung cancer (NSCLC), and an ePoster on the pivotal TACTI-004 Phase ...
07-28 12:00
Immutep’s Eftilagimod Alfa Trials to be Showcased at ESMO 2025
Immutep Ltd ( ($AU:IMM) ) has shared an announcement. Immutep Limited announced...
07-28 09:17
Immutep Ltd Reports Changes in Substantial Holdings
Immutep Ltd ( ($AU:IMM) ) just unveiled an update. Immutep Ltd has announced ch...
07-23 15:57
JPMorgan Chase Reduces Stake in Immutep Ltd
An update from Immutep Ltd ( ($AU:IMM) ) is now available. Immutep Ltd has anno...
07-17 06:38
Immutep Ltd Substantial Holder Increases Stake
Immutep Ltd ( ($AU:IMM) ) just unveiled an update. Immutep Ltd has experienced ...
06-30 15:58
Immutep Announces Initial Efficacy Data And Continued Safety Data From Placebo-Controlled, Double-Blind First-In-Human Phase I Study Evaluating IMP761, LAG-3 Agonist Antibody For Autoimmune Diseases
Initial pharmacological data from placebo-controlled, double-blind Phase I study shows significant T cell suppression and a favourable safety profile at dosing level of 0.9 mg/kgThe substantial reduction in T cell
06-23 20:06
Immutep Announces Positive Update from Phase I Study of IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases
Immutep Limited announces positive initial data from its Phase I study of IMP761, a novel LAG-3 agonist antibody for autoimmune diseases. Results show significant T cell suppression and a favorable safety profile at the 0.9 mg/kg dose level. IMP761 has the potential to silence dysregulated T cells, offering a targeted approach with fewer side effects. The study will continue with higher single ascending doses of 2.5, 7, and 14 mg/kg, with additio...
06-23 12:00
Nuvation Bio's Ibtrozi For ROS1-Positive Lung Cancer Wins FDA Approval
FDA approves Ibtrozi for ROS1+ non-small cell lung cancer based on data from over 300 patients in two pivotal trials showing high response rates.
06-12 02:31
